Oruka Therapeutics, Inc. (ORKA) Stock Ticker
ORKA right now
Market factors today
Unlock the full ORKA picture
About Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
ORKA stock facts
| Ticker symbol | ORKA |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $5.1B |
| CEO | Lawrence Otto Klein |
| Employees | 68 |
| Headquarters | Menlo Park, CA, US |
| IPO date | 1997-08-08 |
| Website | www.orukatx.com |
What you can see for ORKA on Tickr
Live ORKA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ORKA report.
Rankings
FAQ
What is the ticker symbol for Oruka Therapeutics, Inc.?
The ticker symbol for Oruka Therapeutics, Inc. is ORKA, listed on the NASDAQ Global Market.
What is ORKA?
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and…